In March 2019, Novo Nordisk Research Centre China (NNRCC) launched
INNOVO®, an open innovation platform, as we gear up for
increased research collaborations with dynamic innovation forces in
China, building a new pharmaceutical innovation ecosystem and
contributing to research pipelines locally and globally.
By far, INNOVO® has established diverse partnerships
among universities, biotech companies, hospitals, research institutes
and consortium etc, spanning a number of areas, such as diabetes,
obesity, CVD, NASH, AI in drug research and other novel technologies.